Resilience coaching program for young adults with cancer and anxiety or depression
Treatment Development Study of the Promoting Resilience in Stress Management (PRISM) Intervention for Depression and Anxiety in Young Adults With Cancer
This study is testing a coaching program to see if it can help young adults with cancer and anxiety or depression feel better by teaching them skills to manage stress and set goals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Brighton, Massachusetts) |
| Trial ID | NCT06502483 on ClinicalTrials.gov |
What this trial studies
This research focuses on testing the feasibility and acceptability of the Promoting Resilience in Stress Management (PRISM) program, which is designed to help young adults aged 18-30 diagnosed with cancer or desmoid tumors manage psychological symptoms such as anxiety and depression. The intervention consists of six sessions that teach skills related to stress management, goal setting, cognitive reframing, and meaning-making. Participants will undergo screening, complete assessments of their symptoms, and provide feedback on their experience with the program. The study aims to involve up to 15 young adults and their support persons over a period of 2 to 3 months.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 18-30 who have been diagnosed with cancer or a desmoid tumor and are experiencing moderate depressive or anxiety symptoms.
Not a fit: Patients with severe depressive or anxiety symptoms, or those who do not meet the age and diagnosis criteria, may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the mental health and resilience of young adults facing cancer treatment.
How similar studies have performed: Other studies have shown promise in using resilience training for mental health support in cancer patients, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for Participants: * 18-30 years of age * Speak and comprehend English sufficiently to be able to complete study procedures and participate in the program in English * Have been diagnosed with cancer or desmoid tumor at least 6 or more weeks ago * Currently receiving treatment with curative intent or has completed treatment with curative intent for cancer or desmoid tumor no more than 6 months ago * Score 10-14 on the PHQ-9 (Kroenke et al., 1999) or/and score 10-14 on the GAD-7 (Spitzer et al., 2006) during the initial screening assessment. Participant Exclusion Criteria: * Adults unable to consent, individuals who are not yet adults (age \<18), pregnant women, and prisoners. * Individuals who score \<10 on both PHQ-9 and GAD-7. * Patients who score \>14 (indicating moderately severe or severe depressive and/or anxiety symptoms) on PHQ-9 and/or GAD-7 will be ineligible for the current study but will be offered a referral to an appropriate mental health provider for support, if desired. * Individuals who are treated with palliative intent for their disease, those who are diagnosed with cancer less than 6 weeks at the time of screening (we will be able to approach them again after 6 weeks since diagnosis has passed), or those who completed treatment more than 6 months ago will also be ineligible for this study; they will be offered resources for support, if desired. * Individuals who report any suicidality (ideation, plan, and/or intent) at the time of the eligibility screening will also be excluded from the current study, and the appropriate safety measures and/or referral to a mental health provider will be made. Inclusion Criteria for Support Person: -≥ 18 years of age -A friend or family member invited by the study participant to join the 6th PRISM session
Where this trial is running
Brighton, Massachusetts
- Dana-Farber Cancer Institute — Brighton, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Samantha Bento, PhD — Dana-Farber Cancer Institute
- Study coordinator: Samantha Bento, PhD
- Email: samanthap_bento@dfci.harvard.edu
- Phone: 617-632-3041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.